Phase IIIb, observer-blind study to compare immunogenicity of GSK Biologicals' HPV [human papillomavirus]-16/18 L1/AS04 vaccine [Cervarix] versus Gardasil [Quadrivalent Human Papillomavirus (HPV-6,11,16,18,L1 VLP) Recombinant Vaccine Merck & Co., Inc.].

Trial Profile

Phase IIIb, observer-blind study to compare immunogenicity of GSK Biologicals' HPV [human papillomavirus]-16/18 L1/AS04 vaccine [Cervarix] versus Gardasil [Quadrivalent Human Papillomavirus (HPV-6,11,16,18,L1 VLP) Recombinant Vaccine Merck & Co., Inc.].

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary) ; Human papillomavirus vaccine recombinant quadrivalent Merck
  • Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jul 2010 Results presented at the 26th International Papillomavirus Congress according to a media release from GlaxoSmithKline.
    • 29 Oct 2009 18-month results were presented at ADSA 2009.
    • 04 Oct 2009 7-month results were presented at FIGO 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top